Not available
Quote | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Last: | $32.48 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $32.48 |
High: | $0 |
Low: | $0 |
Volume: | 73 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
2024-03-22 17:37:29 ET More on Gilead Sciences Gilead Sciences Finally Starts Succeeding Gilead Sciences: Realizing Financial Projections Is Key Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript) Dividend Roundup: Qual...
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
Message Board Posts | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Subject | By | Source | When |
---|---|---|---|
MomentumIts gaining up | jerseyboy | investorshub | 06/29/2023 10:29:09 PM |
great news | oilin07 | investorshub | 06/27/2023 5:22:29 PM |
what do you make of this data? | TonyJoe1957 | investorshub | 06/27/2023 12:33:09 AM |
Anyone hear anything lately? Want to see this one go | swingingRichard | investorshub | 06/24/2023 5:09:53 PM |
$CBAY The trading last trade up | swingingRichard | investorshub | 06/22/2023 2:55:50 PM |
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...